Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Pharmacol Ther ; 91(6): 1035-43, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22534869

ABSTRACT

Interindividual variation in pharmacodynamic (PD) response to drugs is an ongoing area of research for drugs in clinical development, pre- and postapproval. To characterize how pharmacogenomic (PG ) variations can serves a predictor of differences in PD outcomes, the pharmaceutical industry has incorporated PG /PD analysis into clinical drug development. The Pharmaceutical Research and Manufacturers of America (PhRMA ) and the Industry Pharmacogenomics Working Group (I-PWG) conducted a survey of 16 pharmaceutical companies to ascertain to what extent PG/PD research is being incorporated into drug development. The survey results showed that, while the industry has made some attempt to incorporate PG/PD studies into drug development, application has been inconsistent. Nevertheless, several valid PG/PD markers have since emerged in drug labels. The I-PWG considers PG/PD research an important approach to improving success rates in drug development. This article reports the results of the survey and proposes steps toward increasing the use of PG/PD research by the industry.


Subject(s)
Pharmacogenetics/trends , Pharmacology/trends , Clinical Trials as Topic , DNA/genetics , Data Collection , Data Interpretation, Statistical , Drug Industry , Europe , Internet , Laboratories/standards , Legislation, Drug , Precision Medicine , Quality Control , Specimen Handling/standards , Surveys and Questionnaires , United States
2.
Pharmacogenomics J ; 9(1): 14-22, 2009 Feb.
Article in English | MEDLINE | ID: mdl-18794908

ABSTRACT

Pharmacogenetic association studies have the potential to identify variations in DNA sequence which impact drug response. Identifying these DNA variants can help to explain interindividual variability in drug response; this is the first step in personalizing dosing and treatment regimes to a patient's needs. There are many intricacies in the design and analysis of pharmacogenetic association studies, including having adequate power, selecting proper endpoints, detecting and correcting the effects of population stratification, modeling genetic and nongenetic covariates accurately, and validating the results. At this point there are no formal guidelines on the design and analysis of pharmacogenetic studies. The Industry Pharmacogenomics Working Group has initiated discussions regarding potential guidelines for pharmacogenetic study design and analyses (http://i-pwg.org) and the results from these discussions are presented in this paper.


Subject(s)
Drug Industry/trends , Pharmacogenetics/methods , Research Design/trends , Drug Industry/standards , Endpoint Determination , Humans , Practice Guidelines as Topic , Quality Control , Research Design/standards
3.
Hum Mol Genet ; 10(13): 1387-92, 2001 Jun 15.
Article in English | MEDLINE | ID: mdl-11440991

ABSTRACT

Neurofibromatosis type 1 (NF1) patients that are heterozygous for an NF1 microdeletion are remarkable for an early age at onset and an excessive burden of dermal neurofibromas. Microdeletions are predominantly maternal in origin and arise by unequal crossover between misaligned NF1REP paralogous sequence blocks which flank the NF1 gene. We mapped and sequenced the breakpoints in several patients and designed primers within each paralog to specifically amplify a 3.4 kb deletion junction fragment. This assay amplified a deletion junction fragment from 25 of the 54 unrelated NF1 microdeletion patients screened. Sequence analysis demonstrated that each of the 25 recombination events occurred in a discrete 2 kb recombination hotspot within each of the flanking NF1REPs. Two recombination events were accompanied by apparent gene conversion. A search for recombination-prone motifs revealed a chi-like sequence; however, it is unknown whether this element stimulates recombination to occur at the hotspot. The deletion-junction assay will facilitate the prospective identification of patients with NF1 microdeletion at this hotspot for genotype-phenotype correlation studies and diagnostic evaluation.


Subject(s)
Gene Deletion , Nerve Tissue Proteins/genetics , Neurofibromatosis 1/genetics , Recombination, Genetic , Alleles , DNA/chemistry , DNA/genetics , DNA Mutational Analysis , Family Health , Female , Humans , Male , Neurofibromin 1 , Polymerase Chain Reaction
4.
Am J Hum Genet ; 66(6): 1969-74, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10775528

ABSTRACT

Neurofibromatosis type 1 is a common autosomal dominant disorder caused by mutations of the NF1 gene on chromosome 17. In only 5%-10% of cases, a microdeletion including the NF1 gene is found. We analyzed a set of polymorphic dinucleotide-repeat markers flanking the microdeletion on chromosome 17 in a group of seven unrelated families with a de novo NF1 microdeletion. Six of seven microdeletions were of maternal origin. The breakpoints of the microdeletions of maternal origin were localized in flanking paralogous sequences, called "NF1-REPs." The single deletion of paternal origin was shorter, and no crossover occurred on the paternal chromosome 17 during transmission. Five of the six cases of maternal origin were informative, and all five showed a crossover, between the flanking markers, after maternal transmission. The observed crossovers flanking the NF1 region suggest that these NF1 microdeletions result from an unequal crossover in maternal meiosis I, mediated by a misalignment of the flanking NF1-REPs.


Subject(s)
Chromosomes, Human, Pair 17/genetics , Crossing Over, Genetic/genetics , Genes, Neurofibromatosis 1 , Meiosis/genetics , Sequence Deletion/genetics , Adolescent , Adult , Child , Child, Preschool , Chromosome Breakage/genetics , Female , Haplotypes/genetics , Humans , Male , Microsatellite Repeats/genetics , Pedigree , Polymorphism, Genetic/genetics
6.
Hum Mutat ; 14(5): 387-93, 1999.
Article in English | MEDLINE | ID: mdl-10533064

ABSTRACT

Neurofibromatosis type 1 (NF1) is a common autosomal dominant disorder characterized by a marked variability in expression. A more severe phenotype is frequently observed in the group of patients carrying a large NF1 deletion. To study the extent of the microdeletion in these NF1 patients, we generated a partial physical map of the NF1 flanking region. We describe seven PACs and three new polymorphic dinucleotide repeats located outside the NF1 gene and analyzed 20 unrelated individuals with an NF1 microdeletion in a collaborative study. We detected one individual with a substantially smaller deletion including only the NF1 gene and its three embedded genes. In the other 19 patients, the deletion extended at least 1 Mb. The parental origin of the deletion was determined in 15 individuals and was maternal in 13 and paternal in two cases. The new molecular tools described here can be used to unequivocally diagnose a possible extragenic extension of an NF1 deletion.


Subject(s)
Gene Deletion , Genes, Neurofibromatosis 1 , Neurofibromatosis 1/genetics , Base Sequence , DNA Primers/genetics , Dinucleotide Repeats , Expressed Sequence Tags , Female , Genes, Dominant , Humans , In Situ Hybridization, Fluorescence , Male , Parents , Phenotype , Physical Chromosome Mapping , Polymerase Chain Reaction , Polymorphism, Genetic , Sequence Tagged Sites
7.
Genes Chromosomes Cancer ; 26(4): 376-80, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10534774

ABSTRACT

We have analyzed 98.5% of the coding region of the NF1 gene at the cDNA level in seven NF1 patients who developed malignant peripheral nerve sheath tumors. Seven germline mutations were detected in six individuals: a 6-bp in-frame deletion in exon 28, a splice acceptor mutation in intron 31 resulting in a premature stop of translation, a missense mutation in exon 38, and three total NF1 gene deletions. In one of the patients with a total NF1 gene deletion, a missense mutation in exon 16 on the other NF1 allele was detected. These data indicate that NF1 patients developing malignant neoplasms can have any type of NF1 germline mutation such as a total gene deletion, a frameshift mutation, an in-frame deletion, or a missense mutation. We conclude that in our series no specific type of NF1 germline mutation was found in NF1 individuals with malignancies, but that large NF1 gene deletions were more frequently found in this group than reported for the general population of NF1 individuals. Genes Chromosomes Cancer 26:376-380, 1999.


Subject(s)
Germ-Line Mutation , Neurofibromatosis 1/genetics , Peripheral Nervous System Neoplasms/genetics , Adolescent , Adult , Female , Humans , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...